ABSTRACT

The palliative efficacy of strontium-89 chlori-de has been evaluated retrospectively in pati-ents with painfull spinal metasteses. One patient treated 4 times and totally 89SrCl2 infused 10 ti-mes to 7 patients. Hematologic parameters, pa-in intensity, analgesics consumption and quality of life of patients evaluated weekly during first 3 months. Whilst pain palliation has not been ob-served in 3 of 10 applications, pain palliation has been noted in 7 applications. Toxicity was low with an average %27±11.9 decrease about 4-6 weeks in platelets and %24±19.7 decrease about 6-7 weeks in leucocytes. It is concluded that in this limited series; radionuclide therapy with 89SrCl2 is an effective tool in the palliation of painfull spinal metasteses.